Effectiviness and safety of antidepresants in bipolar depression

Abstract

IntroductionDepressive episodes are associated with higher morbidity, mortality (mostly suicidality. Despite the high prevalence and the devastating impact of this condition, there is a long‐standing debate about its treatment, particularly about the use of antidepressants. International guidelines and expert consensus recommend to avoid AD for bipolar depression, or to use AD with caution and as second line treatment only if the depressive episode shows poor response to mood stabilizers (MS) and to some second generation antipsychotics (SGA) (cariprazine, lurasidone, quetiapine and olanzapine combined with fluoxetine) in monotherapy and in combination. Contrary to the advice of guidelines and experts, 50%–80% of acute bipolar depressive episodes are treated with AD in everyday clinical practice.ObjectivesTo evaluate the effectiveness and the safety of AD acute treatment in patients with bipolar depressionMethodsLiterature review (PubMed)ResultsShort‐term safety, switching and suicidality did not differ significantly, and no suicide attempt was observed. Concerning long‐term safety, patients with bipolar depression had a significant reduction of depressive and total recurrences during the first year.ConclusionsAcute AD treatment of bipolar depression is effective in the short term and safe in the short‐ and long‐termDisclosureNo significant relationships.